BCDA:NSD-BioCardia, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.37

Change

0.00 (0.00)%

Market Cap

USD 0.03B

Volume

0.03M

Average Target Price

USD 10.25 (+332.49%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.

Company Website : http://www.biocardia.com

Address : 125 Shoreway Road, San Carlos, CA, United States, 94070

Employees : 20

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.07

52 Week High : 6.75

Short Ratio : 0.16

52 Week Low : 2.01

Shorted Shares : 8,994

200 Day Moving Average : 3.04

Shorted Shares Previous Month : 23,569

50 Day Moving Average : 2.39

Shares Held By Insiders : 769.02%

Shares Held by Institutions : 3.06%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

N/A

 USD32.18B N/A N/A
MRNA Moderna, Inc

N/A

 USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

N/A

 USD24.87B N/A N/A
RPRX Royalty Pharma plc

N/A

 USD24.33B 36.15 9.83
GMAB Genmab A/S

N/A

 USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

N/A

 USD19.73B N/A N/A
INCY Incyte Corporation

N/A

 USD18.93B 47.64 35.20

ETFs Containing BCDA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -35.60% 25% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.60% 25% F 23% F
Trailing 12 Months  
Capital Gain -38.92% 19% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.92% 19% F 18% F
Trailing 5 Years  
Capital Gain 2,755.42% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,755.42% 98% A+ 99% A+
Average Annual (5 Year Horizon)  
Capital Gain 241.68% N/A N/A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 241.68% N/A N/A 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 260.88% N/A N/A 3% F
Risk Adjusted Return 92.64% N/A N/A 91% A-
Market Capitalization 0.03B 11% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.70 75% C 91% A-
Price/Book Ratio 3.99 51% F 32% F
Price / Cash Flow Ratio -3.04 37% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -611.71% 5% F 2% F
Return on Invested Capital -461.31% 2% F 1% F
Return on Assets -117.92% 3% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.16 93% A 92% A-
Short Percent 0.26% 97% A+ 92% A-
Beta 2.07 23% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector